ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 — RESULTS OF OPERATION AND FINANCIAL CONDITION
On February9, 2018,ImmunoGen,Inc. (Nasdaq: IMGN) issued a press release to announce the company’s financial results for the quarter and year ended December31, 2017. The press release announcing financial results for the quarter and year ended December31, 2017 is included as Exhibit99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d): The following exhibit is being furnished herewith:
IMMUNOGEN INC ExhibitEX-99.1 2 a18-5715_1ex99d1.htm EX-99.1 Exhibit 99.1 ImmunoGen Reports Pipeline Progress and 2017 Operating Results Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with Patients Enrolling in Phase 1 Study of IMGN632 and Phase 1 Data Presented at ASH for IMGN779 Conference Call to be Held at 8:00 a.m. ET Today WALTHAM,…To view the full exhibit click here
About ImmunoGen,Inc. (NASDAQ:IMGN)
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.